Effect of p-isopropoxyphenylsuccinimide monohydrate on the anticonvulsant action of carbamazepine, phenobarbital, phenytoin and valproate in the mouse maximal electroshock-induced seizure model

Pharmacological Reports

Volumn 62, Issue 1, 2010, Pages 194-202

  Łuszczki, Jarogniew J ^a,b   Kocharov, Sergey L ^c   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c INSTITUTE OF ORGANIC CHEMISTRY   (Armenia)

Author keywords

Antiepileptic drugs; Maximal electroshock induced seizures; Pharmacokinetic pharmacodynamic interaction; Succinimide derivative

Indexed keywords

4 ISOPROPOXYPHENYLSUCCINIMIDE; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG POTENTIATION; ELECTRIC SHOCK; GRIP STRENGTH; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NONHUMAN; SEIZURE; SKELETAL MUSCLE; SWISS WEBSTER MOUSE;

EID: 77950795860     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70257-7     Document Type: Article

References (19)

1. Boissier JR, Tardy J, Diverres JC: A simple novel method to explore tranquilizer activity: the chimney test (in French). Med Exp (Basel), 1960, 3, 81-84.
2. Cadart M, Marchand S, Pariat C, Bouquet S, Couet W: Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharm Res, 2002, 19, 209-214.
3. Kamiński K, Obniska J: Synthesis and anticonvulsant properties of new 1-(2-pyridinyl)-3-substituted pyrrolidine-2,5-dione derivatives. Acta Pol Pharm Drug Res, 2008,65,457-465.
4. Lange J, Rump S, Gałecka E, Ilczuk I, Lechowska-Postek M, Rabsztyn T: Synthesis and properties of new cyclic derivatives of succinic acid with anticonvulsant activity. Pharmazie, 1977, 32, 82-84.
5. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949,96,99-113.
6. Löscher W, Fassbender CP, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res, 1991, 8, 79-94.
7. Löscher W, Fiedler M: The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures. Epilepsy Res, 2000, 38, 231-248.
8. Łuszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ: Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol, 2009,602,298-305.
9. Łuszczki JJ, Czernecki R, Wojtal K, Borowicz KK, Czuczwar SJ: Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm, 2008, 115,1485-1493.
10. Łuszczki JJ, Kocharov SL, Czuczwar SJ: N-(anilinomethyl)-p-isopropoxyphenyl-succinimide potentiates the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock-induced seizure model. Neurosci Res, 2009, 64, 267-272.
11. Łuszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedeberg's Arch Pharmacol, 2006, 373, 169-181.
12. Łuszczki JJ, Sawicka KM, Kozińska J, Borowicz KK, Czuczwar SJ: Furosemide potentiates the anticonvulsant action of valproate in the mouse maximal electroshock seizure model. Epilepsy Res, 2007, 76, 66-72.
13. Łuszczki JJ, Świader M, Czuczwar M, Kiś J, Czuczwar SJ: Interactions of tiagabine with some antiepileptics in the maximal electroshock in mice. Pharmacol Biochem Behav, 2003, 75, 319-327.
14. Łuszczki JJ, Wójcik-Ćwikła J, Andres MM, Czuczwar SJ: Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology, 2005, 30, 958-973.
15. Meyer OA, Tilson HA, Byrd WC, Riley MT: Amethod for the routine assessment of fore- and hindlimb grip strength of rats and mice. Neurobehav Toxicol, 1979, 1, 233-236.
16. Stables JP, Kupferberg HJ: Chapter 16 - The NIH Anti-convulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. In: Molecular and cellular targets for anti-epileptic drugs. Eds. Avanzini G, Regesta G, Tanganelli P, Avoli M, John Libbey, London, 1997,191-198.
17. Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J: Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature, 1986, 321, 864-866.
18. White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH: Discovery and preclinical development of antiepileptic drugs. In: Antiepileptic drugs. Fifth edition. Eds. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams & Wilkins, Philadelphia, 2002,36-48.
19. Zejc A, Obniska J, Wilimowski M, Rutkowska M, Witkowska M, Barczyńska J, Kedzierska-Goździk L et al.: Synthesis and anticonvulsant properties of some arylsuccinate methylpyridylimides. Pol J Pharmacol Pharm, 1990,42,69-77.